GLIS Family Zinc Finger 2 (GLIS2) is a critical Krüppel-like zinc finger transcription factor that plays a pivotal role in kidney development and hematopoiesis. In pediatric oncology, the recurrent inv(16)(p13.3q24.3) chromosomal translocation fuses GLIS2 with CBFA2T3, generating the oncogenic CBFA2T3-GLIS2 fusion protein. This fusion is the hallmark driver of a highly refractory, poor-prognosis subtype of pediatric Acute Megakaryoblastic Leukemia (AMKL) known as the RAM phenotype. Targeting GLIS2, its fusion partner CBFA2T3, or its transcriptional co-factors represents a highly specialized and urgent frontier in hematological oncology and nephrology drug discovery.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for GLIS2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GLIS2 Recombinant Protein (Zinc Finger Domain) High purity (>90%), Endotoxin controlled. Sequence Verified. Optimized for DNA-binding and PPI assays. |
View GLIS2 Products |
| Gene Delivery | GLIS2 / CBFA2T3-GLIS2 Promise-ORF Lentivirus Full-length ORF or fusion gene for stable cell line construction in leukemia modeling. |
View GLIS2 Products |
| Benchmark Ab | Anti-GLIS2 Recombinant Antibody High-affinity positive control for Western Blot, ChIP-seq, and ELISA verification. |
View GLIS2 Products |
| Validator | GLIS2 siRNA Set For target knockdown validation in megakaryoblastic cell lines. |
View GLIS2 Products |
| Related Target A | CBFA2T3 The essential fusion partner in pediatric AMKL; critical for modeling the oncogenic fusion complex. |
View CBFA2T3 Products |
| Related Target B | EP300 Transcriptional co-activator recruited by GLIS2/CBFA2T3-GLIS2; key target for disrupting transcriptional activation. |
View EP300 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Reconstituting zinc-finger DNA binding activity in vitro | Sequence-verified zinc finger domain proteins with optimized folding and zinc-ion preservation. |
| Modeling the oncogenic CBFA2T3-GLIS2 fusion in cell lines | Lentiviral vectors containing sequence-validated fusion genes for stable cellular expression. |
| Lack of reliable positive controls for ChIP/Western Blot | Recombinant biosimilar-grade antibodies verified for sequence accuracy and target binding. |
| Off-target assay noise in transcriptional screening | Sequence-verified siRNA sets included to confirm target-specific gene knockdown. |
Live GLIS2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for GLIS2 therapeutics is intensifying, with major players shifting focus from traditional chemotherapy to targeted transcriptional disruption and protein degradation. As first-generation therapies reach the clinic, the next wave of R&D is targeting the specific protein-protein interactions (PPI) of the CBFA2T3-GLIS2 fusion or utilizing molecular glues to induce its degradation. Because GLIS2 is an intracellular transcription factor, therapeutic modalities are heavily focused on small-molecule inhibitors, PROTACs, and RNA-based therapeutics (siRNA/mRNA) designed to halt the aberrant transcriptional program driving megakaryoblastic self-renewal.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitors | Academic Consortia, Biotech Startups | Pediatric AMKL (RAM Phenotype) | Protein-Protein Interaction Assay (Need high-purity GLIS2 and EP300 proteins) |
| Targeted Protein Degraders (PROTACs/Glues) | Oncology-focused Biotechs | Refractory Acute Myeloid Leukemia | Degradation Validation (Need Lentivirus for stable expression and benchmark antibodies) |
| RNA Therapeutics (siRNA) | RNAi Therapeutics Developers | Nephronophthisis, AMKL | Knockdown Efficiency Assay (Need sequence-verified siRNA sets and RT-qPCR controls) |